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The role of paracrine signaling by vascular endothelial growth factor (VEGF) in the forma-
tion and maintenance of blood vessels has been studied extensively. In this issue, Lee et al. 
(2007) report unexpected results showing that endogenous VEGF produced by endothelial 
cells is also crucial for vascular homeostasis.The function of vascular endothe-
lial growth factors (VEGFs) in the 
formation and growth of blood ves-
sels has been well characterized. In 
addition to VEGFs, vascular growth 
also depends on a bilateral paracrine 
signaling of factors including plate-
let-derived growth factor (PDGF) 
and angiopoietins (Ang), which are 
involved in stabilizing the vasculature 
and protecting the endothelium by 
providing survival signals (Figure 1). 
The prevailing view is that an endo-
thelial cell protects itself by secret-
ing PDGF-B that acts on pericytes 
(which cover blood vessels) that in 
turn secrete Ang1, resulting in the 
stabilization of blood vessels (von Tell 
et al., 2006). Endothelial cells were 
not thought to produce VEGF until 
recently (Maharaj et al., 2006), but in 
this issue, Lee et al. (2007) now reveal 
the surprising result that endogenous 
VEGF produced by endothelial cells 
is crucial for vascular homeostasis. 
These authors demonstrate that in 
the absence of their own autocrine 
VEGF, endothelial cells commit sui-
cide causing collateral damage by Figure 1. Paracrine and Autocrine Effects of Growth Factors in Capillaries
(A) During steady-state conditions paracrine angiopoietin-1 (Ang1) and low levels of para-
crine vascular endothelial growth factor (VEGF) are produced by pericytes and other cell 
types associated with the endothelium. Lee et al. (2007) show that VEGF produced by endo-
thelial cells promotes intracellular autocrine stimulation of VEGFR2 that supports endothelial 
cell survival. (VEGFR-2-P, phosphorylated VEGFR2.) 
(B) Several pathways are activated during the formation of new blood vessels (angiogen-
esis). VEGF production increases in response to ischemia/tissue hypoxia that is in part 
responsible also for autocrine production of Ang2 involved in pericyte detachment (Yan-
copoulos et al., 2000). VEGF and placental growth factor (PlGF) as well as stroma-derived 
factor-1 (SDF-1)—produced by perivascular myofibroblasts—recruit mononuclear cells 
into the perivascular space by binding to the receptors VEGFR1 and CXCR4, respectively 
(Grunewald et al., 2006; Luttun et al., 2002). These cells and related macrophages pro-
duce additional angiogenic factors including VEGF, VEGF-C, and VEGF-D, and they may in 
some cases be responsible for why tumors are refractory to continued anti-VEGF treatment 
(Shojaei et al., 2007). Cell 130, August 24, 2007 ©2007 Elsevier Inc. 591
blocking vascular traffic and inducing 
thrombosis. Accumulation of such 
damage in various regions of the 
entire vascular system leads to cata-
strophic circulatory collapse and the 
death of mice deficient in endothelial 
VEGF (Lee et al., 2007).
Lee et al. specifically deleted 
VEGF in the endothelial cells and in 
mature hematopoietic cells of mice 
by using a vascular endothelial cad-
herin-driven Cre recombinase. They 
found that mice that lacked VEGF in 
their endothelial cells had signs of 
severe failure of the cardiovascular 
system such as hemorrhages, micro-
infarcts, endothelial cell rupture, 
and vascular constriction. Interest-
ingly, Lee et al. found no phenotype 
when they deleted only one allele of 
the endothelial VEGF gene in mice 
even though a single VEGF allele is 
not sufficient to support develop-
ment of mouse embryos (Carme-
liet, 2005; Red-Horse et al., 2007). 
Furthermore, although prior studies 
have shown that intracellular VEGF 
also regulates hematopoietic stem 
cell survival (Gerber et al., 2002), 
such an effect was not seen in the 
present study, where more mature 
cells were targeted.
Lee et al. report that exogenous 
VEGF is unable to compensate for 
the loss of endogenous VEGF in 
endothelial cells, despite the fact 
that signaling through VEGFR2 
activates several downstream 
pathways, including the PI3K/AKT 
pathway responsible for cell sur-
vival (Olsson et al., 2006). VEGFR2 
has been reported to signal for cell 
survival also in the nervous system, 
where bouts of relative hypoxia can 
provoke VEGF expression. This 
function may be subtly impaired in 
amyotrophic lateral sclerosis (ALS), 
which is characterized by the degen-
eration of motor neurons (Lambre-
chts and Carmeliet, 2006). Indeed, 
patients with ALS express geneti-
cally distinguishable VEGF alleles 
that show reduced VEGF gene tran-
scription and translation, decreased 
VEGF levels, and increased disease 
susceptibility.592 Cell 130, August 24, 2007 ©2007 ElThe Lee et al. findings reveal new 
insights into VEGF signaling in endo-
thelial cells. McDonald and colleagues 
have shown that removing exog-
enous paracrine VEGF—for example 
by using soluble VEGFR—led to prun-
ing of the vascular network in tissues 
characterized by a fenestrated endo-
thelium (Kamba et al., 2006). In adult 
mice, treatment with a low-molecular 
weight tyrosine kinase inhibitor that 
targets VEGFR2 as well as some 
other tyrosine kinases resulted in an 
even greater reduction in blood ves-
sel density. The extracellular inhibi-
tors of VEGF did not affect the sur-
vival of endothelial cells in culture; 
however, Lee et al. (2007) now show 
that a small molecular weight tyrosine 
kinase inhibitor acting at the intracel-
lular level inhibited survival of endo-
thelial cells if no other growth factors 
were present. This may in part relate 
to the internal autocrine VEGF loop in 
endothelial cells. Results from inhibi-
tion of VEGF signaling indicate that 
both autocrine and paracrine VEGF—
which is produced in small amounts 
by many nonendothelial cells in vari-
ous tissues—are crucial for mainte-
nance of blood vessels. That tyro-
sine kinase inhibitors and antibodies 
against VEGF could cause pruning of 
normal blood vessels is an important 
issue because these compounds are 
used in the clinics to prevent blood 
vessel formation in tumors.
The importance of intracellular 
autocrine VEGF produced by endo-
thelial cells for supporting the vas-
culature is surprising. If single genes 
prove as complex as VEGFs, it is 
unlikely that even systems biology 
can produce a reasonable model 
of the biological complexity of the 
numerous vascular signal transduc-
tion networks for a long time to come. 
In addition, other members of the 
VEGF family can also function in neo-
vascular growth. VEGF-C and VEGF-
D, originally thought to be involved 
only in lymphangiogenesis, can also 
participate in pathological angiogen-
esis (Laakkonen et al., 2007). Further-
more VEGF-B—currently the least 
studied member of the family—could sevier Inc.promote vascular functions predomi-
nantly in tissues such as heart and 
brown adipose tissue, where it is 
highly expressed. This would make 
the VEGF dynasty one of the most 
influential gene families known.
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